Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) saw a large drop in short interest in January. As of January 15th, there was short interest totalling 3,750,000 shares, a drop of 67.6% from the December 31st total of 11,570,000 shares. Based on an average daily volume of 52,100,000 shares, the short-interest ratio is currently 0.1 days.

Conduit Pharmaceuticals Stock Performance

Shares of NASDAQ:CDT traded down $0.40 during midday trading on Wednesday, hitting $2.67. The company’s stock had a trading volume of 297,674 shares, compared to its average volume of 1,442,833. Conduit Pharmaceuticals has a 12-month low of $2.51 and a 12-month high of $392.00. The business’s 50 day simple moving average is $7.91 and its 200 day simple moving average is $12.09.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.